Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 36.1
edited by manuelmenendez
on 2025/02/02 00:50
on 2025/02/02 00:50
Change comment:
There is no comment for this version
To version 47.1
edited by manuelmenendez
on 2025/03/03 22:46
on 2025/03/03 22:46
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,9 +2,9 @@ 2 2 ((( 3 3 (% class="container" %) 4 4 ((( 5 -= //A new tridimensional diagnostic framework for CNS diseases// = 5 += //A new tridimensional diagnostic framework for complex CNS diseases// = 6 6 7 -This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 7 +This project is focused on developing a novel nosological and diagnostic framework for complex CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 8 8 We aim to create a structured, interpretable, and scalable diagnostic tool. 9 9 ))) 10 10 ))) ... ... @@ -17,31 +17,21 @@ 17 17 18 18 = **Overview** = 19 19 20 +The classification and diagnosis of central nervous system (CNS) diseases have long been constrained by traditional, phenotype-based approaches that often fail to capture the complex interplay of pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes. 20 20 21 - Theclassification anddiagnosisof central nervoussystem (CNS) diseaseshavelong been constrainedby traditionalphenotype-basedpproaches,whichoften failcapture the complexpathophysiologicalmechanisms,molecular biomarkers, andneuroanatomicalchanges thatdrivedisease progression.Neurodegenerative andpsychiatric disorders,forxample,exhibitsignificant clinicaloverlap,co-pathology, andheterogeneity, making currentdiagnosticmodelsinsufficient.22 +**Neurodiagnoses** redefines this landscape by integrating advanced AI with multi-modal data—including genetics, neuroimaging, biomarkers, and digital health records—to create a more precise, scalable, and data-driven diagnostic system. 22 22 23 - This projectproposesanewdiagnostic framework—onethat shifts fromsymptom-basedclassificationstoanetiology-driven,tridimensionalsystem. Byintegratinggenetics, proteomics, neuroimaging,computationalmodeling,andAI-poweredannotations,this approachaimsto providemore precise,scalable, and biologically groundedmethodfordiagnosingand managing CNS diseases.24 +Additionally, **Neurodiagnoses is now expanding into disease prediction and biomarker estimation**, integrating state-of-the-art machine learning models to enhance precision diagnostics and disease progression forecasting. 24 24 25 - The AI-powered annotationsystemplays a critical role by structuring, interpreting,and tracking multi-modal data, ensuringreal-time disease progression analysis, cliniciandecisionsupport, andpersonalized treatment pathways.26 +On this page, you will find: 26 26 27 -=== **Project Aim** === 28 +* Detailed descriptions of both the clinical diagnostic tools and the research framework. 29 +* Access to our AI models, data processing pipelines, and digital twin simulations. 30 +* Collaborative resources for researchers, clinicians, and AI developers. 31 +* Guidelines and instructions on how to contribute to and expand the project. 28 28 29 -The project aims to develop a tridimensionaldiagnosticframeworkwith anAI-powered annotationsystem, integrating etiology, molecular biomarkers, and neuroanatomoclinical correlations for precise, standardized, and scalable CNS disease diagnostics.33 +== **The role of AI-powered annotation** == 30 30 31 -The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on: 32 - 33 -* **Axis 1**: Etiology (genetic or other causes of diseases). 34 -* **Axis 2**: Molecular Markers (biomarkers). 35 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). 36 - 37 -This methodology enables: 38 - 39 -* Greater precision in diagnosis. 40 -* Integration of incomplete datasets using AI-driven probabilistic modeling. 41 -* Stratification of patients for personalized treatment. 42 - 43 -== **The Role of AI-Powered Annotation** == 44 - 45 45 To enhance standardization, interpretability, and clinical application, the framework integrates an AI-powered annotation system, which: 46 46 47 47 * Assigns structured metadata tags to diagnostic features. ... ... @@ -50,6 +50,34 @@ 50 50 * Improves AI model transparency through interpretability tools (e.g., SHAP analysis). 51 51 * Facilitates decision-making for clinicians by linking annotations to standardized biomedical ontologies (SNOMED, HPO). 52 52 43 +Neurodiagnoses provides **two complementary AI-driven diagnostic approaches**: 44 + 45 +1. **Probabilistic Diagnosis** 46 + * AI assigns probability scores to multiple possible diagnoses based on biomarker, imaging, and clinical data. 47 + * Useful for differential diagnosis and treatment decision-making. 48 + 49 +2. **Tridimensional Diagnosis** 50 + * Diagnoses are structured based on: 51 + - **(1) Etiology** (genetic, autoimmune, metabolic, infectious). 52 + - **(2) Molecular Biomarkers** (amyloid-beta, tau, inflammatory markers, EEG patterns). 53 + - **(3) Neuroanatomoclinical Correlations** (brain atrophy, connectivity alterations). 54 + * This approach enables precise disease subtyping and biologically meaningful classification, particularly useful for tracking progression over time. 55 + 56 +Both systems will be offered for every patient case, allowing clinicians to compare AI-generated probabilistic diagnosis with a structured tridimensional classification. 57 + 58 +== **Disease Prediction and Biomarker Estimation** == 59 + 60 +Neurodiagnoses is also implementing **biomarker prediction and disease progression modeling**, using advanced machine learning techniques: 61 + 62 +* **Biomarker Prediction:** 63 + - Estimation of fluid-based and neuroimaging biomarkers without invasive testing. 64 + - Multi-modal machine learning models for predicting molecular and clinical markers. 65 + 66 +* **Disease Progression Modeling:** 67 + - AI-driven forecasts for neurodegenerative disease evolution. 68 + - Probabilistic disease conversion models (e.g., MCI to AD, Parkinson's prodromal phases). 69 + - Survival models and risk stratification for precision medicine applications. 70 + 53 53 == **The case of neurodegenerative diseases** == 54 54 55 55 There have been described these 3 diagnostic axes: ... ... @@ -58,25 +58,18 @@ 58 58 59 59 * ((( 60 60 **Axis 1: Etiology** 61 - 62 62 * //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. 63 63 * //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. 64 64 * //Tests//: Genetic testing, lifestyle, and cardiovascular screening. 65 - 66 - 67 67 ))) 68 68 * ((( 69 69 **Axis 2: Molecular Markers** 70 - 71 71 * //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression. 72 72 * //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology. 73 73 * //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET). 74 - 75 - 76 76 ))) 77 77 * ((( 78 78 **Axis 3: Neuroanatomoclinical** 79 - 80 80 * //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments. 81 81 * //Examples//: Hippocampal atrophy correlating with memory deficits. 82 82 * //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations. ... ... @@ -86,7 +86,7 @@ 86 86 87 87 This system enhances: 88 88 89 -* **Research**: By stratifying patients, reduc escohort heterogeneity in clinical trials.100 +* **Research**: By stratifying patients, reducing cohort heterogeneity in clinical trials. 90 90 * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking. 91 91 92 92 == How to Contribute == ... ... @@ -94,6 +94,8 @@ 94 94 * Access the `/docs` folder for guidelines. 95 95 * Use `/code` for the latest AI pipelines. 96 96 * Share feedback and ideas in the wiki discussion pages. 108 +* Join our [[Community on EBRAINS>>https://community.ebrains.eu/_ideas/-OJHTZrpKrrrkx-u0djj/about]] 109 +* Join the [[Discussion Forum at GitHub>>https://github.com/Fundacion-de-Neurociencias/neurodiagnoses/discussions]] 97 97 98 98 == Key Objectives == 99 99 ... ... @@ -100,17 +100,17 @@ 100 100 * Develop interpretable AI models for diagnosis and progression tracking. 101 101 * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources. 102 102 * Foster collaboration among neuroscientists, AI researchers, and clinicians. 116 +* Provide a dual diagnostic system: 117 + ** Probabilistic Diagnosis – AI assigns multiple traditional possible diagnoses with probability percentages. 118 + ** Tridimensional Diagnosis – AI structures diagnoses based on etiology, biomarkers, and neuroanatomical correlations. 119 +* Implement disease prediction models for neurodegenerative conditions. 120 +* Predict biomarkers from non-invasive data sources. 103 103 104 104 == Who has access? == 105 105 106 -We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! 124 +We welcome contributions from the global community. Join us as we transform CNS diagnostics and drive precision medicine forward through a collaborative, open-source approach. Let’s build the future of neurological diagnostics together! 107 107 ))) 108 108 109 - 110 - 111 - 112 - 113 - 114 114 (% class="col-xs-12 col-sm-4" %) 115 115 ((( 116 116 {{box title="**Contents**"}} ... ... @@ -129,3 +129,4 @@ 129 129 * [[to-do-list>>to-do-list]] 130 130 ))) 131 131 ))) 145 +